7月28日，Repligen盘中上涨15.35%，报149.47美元/股，成交额9878.79万美元。
消息面上，公司当日盘前公布第二季度财报，业绩全面超出市场预期。Q2调整后每股收益0.54美元，远超市场预期的0.45美元，同比大增45.95%；营收2.041亿美元，高于预期的2.015亿美元，同比增长11.9%。与此同时，公司上调全年指引，预计调整后每股收益2.03至2.09美元（此前为1.97至2.05美元），营收8.13亿至8.35亿美元（此前为8.03亿至8.33亿美元），均高于分析师预期。
Repligen是全球生物制剂生产关键设备及耗材的领先供应商，产品覆盖单克隆抗体、重组蛋白、疫苗及细胞与基因疗法等生物制药工艺领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.